|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Product sales, net | |||||
| Cost of goods sold | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Benefit from reversal of accrued payroll taxes (Note 12) | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other expense, net | |||||
| Interest expense, net | |||||
| Loss before income taxes | |||||
| Income tax expense (benefit) | |||||
| Net loss | |||||
| Deemed dividend for beneficial conversion of Series A Convertible Preferred Stock | |||||
| Net income (loss) attributable to common stockholders | |||||
| Weighted average common shares outstanding, basic (in shares) | |||||
| Weighted average common shares outstanding, diluted (in shares) | |||||
| Net loss per common share, basic (in USD per share) | |||||
| Net loss per common share, basic diluted (in USD per share) |
Loading...